It is therefore tempting to hypothesize that inhibition of USP22 activity could represent an innovative approach to target HER2+-BC and that simultaneous pharmacologic stimulation of UPR-signaling could potentiate these effects. This evidence concerns the gene USP22 and breast cancer.